logo
  Join        Login             Stock Quote

Orphan Status For Allos Drug In EU

 June 21, 2010 12:31 AM
 


Recently, Allos Therapeutics (ALTH) received orphan drug status from the European Commission (EC) for Folotyn (pralatrexate) for the treatment of cutaneous T-cell lymphoma (CTCL). The candidate is being evaluated in an early-stage study to treat patients suffering from relapsed or refractory CTCL.

Furthermore, Allos intends to conduct a late-stage study to evaluate the candidate in combination with systemic bexarotene versus only systemic bexarotene in CTCL patients who have not responded to at least one prior systemic therapy. However, before initiating the study, the company intends to carry out an early-stage trial to determine the maximum tolerated dose of the combination. The early-stage study is expected to commence in 2010.

CTCL comprises approximately 2% to 3% of the estimated 66,000 new cases of non-Hodgkin's lymphoma diagnosed each year in the US, according to data released by the Lymphoma Research Foundation. CTCLs comprise a group of sluggish non-Hodgkin's T-cell lymphomas, which mainly manifest in the skin.

The orphan drug designation brings with it ten years of marketing exclusivity subsequent to the candidate getting marketing approval in the European Union. Additionally, this status, which is based on a favorable opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), provides several other benefits such as free protocol assistance on clinical trials, a reduced Marketing Authorisation Application (MAA) filing fee and the possibility for grant funding. Furthermore, the designation facilitates the development of drugs that may provide significant benefit to patients suffering from rare, life-threatening diseases.

Folotyn already enjoys orphan drug status from the EC for other indications such as peripheral T-cell lymphoma (PTCL) and non-papillary transitional cell carcinoma (TCC) of the urinary bladder, a form of bladder cancer. Folotyn is currently approved by the US Food and Drug Administration (FDA) for treating patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The drug received accelerated FDA approval in September 2009 and is the only marketed product at Allos.

We believe Folotyn's approval for the PTCL indication will provide major relief to patients suffering from this disease as prior to Folotyn there was no approved drug. While the drug has been available to patients since October, it was launched commercially in January 2010.

The company's efforts to expand Folotyn's label into other indications is encouraging. We believe that Folotyn, if approved for any of the additional indications can prove to be a major revenue earner for the company.

Currently we are Neutral on Allos Therapeutics.
iOnTheMarket Premium
Advertisement

Advertisement


Comments Closed


rss feed

Latest Stories

article imageSanDisk Corporation (SNDK) Q1 Earnings Preview: Heads or Tails on Pop or Drop

SanDisk Corporation (NASDAQ:SNDK) will publish its first quarter 2014 financial results press release via read on...

article imageEstee Lauder Companies Inc (EL): Goldman Sachs is Convicted EL Will Make Your Portfolio Prettier

Want to freshen up your portfolio? Goldman Sachs say to add Estee Lauder Companies Inc (NYSE:EL). The read on...

article imageYahoo! Inc. (YHOO) Q1 Earnings Preview: Another Bullish Surprise Coming

Yahoo! Inc. (NASDAQ:YHOO) will discuss the company's financial results for the first quarter ended March read on...

article imageThe Coca-Cola Company (KO) Q1 Earnings Preview: Guidance About to Fizzle?

The Coca-Cola Company (NYSE:KO) plans to release its first quarter earnings results before the market opens read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.